GFAP and Alzheimer disease: WB assays and quantification results showed that GlcNAc administration significantly restored the level of O-GlcNAcylation (Fig. 8f, g), but also significantly reduced the levels of GFAP, IL-1β and TNF-α in AD astrocytes (Fig. 8f, h–j).